Related Experiment Video

Updated: Aug 17, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
07:29

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis

Published on: November 12, 2015

Topical cyclosporin A in the management of vernal keratoconjunctivitis

V Gupta1, P K Sahu

  • 1Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. gupta_v@mailcity.com

Eye (London, England)
|April 25, 2001
PubMed

Insights

Topical cyclosporin (CsA) effectively treats vernal keratoconjunctivitis in children. Most patients experienced symptom relief within seven days, demonstrating CsA

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Vernal keratoconjunctivitis (VKC) is a bilateral, itching ocular allergic condition.
  • Current treatments for VKC have limitations.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical cyclosporin A (CsA) for treating pediatric VKC.

Main Methods:

  • A prospective, randomized, double-masked trial was conducted.
  • Twenty-four children (ages 5-16) with VKC received either CsA or placebo for 4 months.

Main Results:

  • 11 out of 12 children treated with CsA showed symptomatic improvement within 7 days.
  • Only 3 children in the placebo group reported mild symptomatic improvement.

Conclusions:

  • Topical cyclosporin A is a safe and effective therapeutic option for children diagnosed with vernal keratoconjunctivitis.
Abstract

More Related Videos

Intracameral Injection in Rats with Low Risk of Adverse Effects06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...